PT  - JOURNAL ARTICLE
AU  - Mark P.S. Dunphy
AU  - Jason S. Lewis
TI  - Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET
AID  - 10.2967/jnumed.108.057281
DP  - 2009 May 01
TA  - Journal of Nuclear Medicine
PG  - 106S--121S
VI  - 50
IP  - Suppl 1
4099  - http://jnm.snmjournals.org/content/50/Suppl_1/106S.short
4100  - http://jnm.snmjournals.org/content/50/Suppl_1/106S.full
SO  - J Nucl Med2009 May 01; 50
AB  - This review article discusses PET agents, other than 18F-FDG, with the potential to monitor the response to therapy before, during, or after therapeutic intervention. This review deals primarily with non–18F-FDG PET tracers that are in the final stages of preclinical development or in the early stages of clinical application for monitoring the therapeutic response. Four sections related to the nature of the tracers are included: radiotracers of DNA synthesis, such as the 2 most promising agents, the thymidine analogs 3′-18F-fluoro-3′-deoxythymidine and 18F-1-(2′-deoxy-2′-fluoro-β-d-arabinofuranosyl)thymine; agents for PET imaging of hypoxia within tumors, such as 60/62/64Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone) and 18F-fluoromisonidazole; amino acids for PET imaging, including the most popular such agent, l-[methyl-11C]methionine; and agents for the imaging of tumor expression of androgen and estrogen receptors, such as 16β-18F-fluoro-5α-dihydrotestosterone and 16α-18F-fluoro-17β-estradiol, respectively.